WO2003006429A1 - Synthesis of taxol enhancers - Google Patents
Synthesis of taxol enhancers Download PDFInfo
- Publication number
- WO2003006429A1 WO2003006429A1 PCT/US2002/021716 US0221716W WO03006429A1 WO 2003006429 A1 WO2003006429 A1 WO 2003006429A1 US 0221716 W US0221716 W US 0221716W WO 03006429 A1 WO03006429 A1 WO 03006429A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- nhr
- phenyl
- aliphatic
- Prior art date
Links
- 0 *CC(N(*)*(*)C(*C(N(N(*)C(*)=S)O*)=O)=O)=S Chemical compound *CC(N(*)*(*)C(*C(N(N(*)C(*)=S)O*)=O)=O)=S 0.000 description 1
- GEASCWHPMRLZNR-UHFFFAOYSA-N CC(C(NN(C)C1SC1c(cccc1OC)c1OC)=O)C(NN(C)C(c1cccc(OC)c1OC)=S)=O Chemical compound CC(C(NN(C)C1SC1c(cccc1OC)c1OC)=O)C(NN(C)C(c1cccc(OC)c1OC)=S)=O GEASCWHPMRLZNR-UHFFFAOYSA-N 0.000 description 1
- XLTZYCMIMIOJTQ-UHFFFAOYSA-O CC1(C(N(c2ccccc2)NC(CC(NN(C(c2ccccc2OC(C)=O)=S)c2ccccc2)=O)=O)=S)C([OH+]C(C)=O)=CC=CC1 Chemical compound CC1(C(N(c2ccccc2)NC(CC(NN(C(c2ccccc2OC(C)=O)=S)c2ccccc2)=O)=O)=S)C([OH+]C(C)=O)=CC=CC1 XLTZYCMIMIOJTQ-UHFFFAOYSA-O 0.000 description 1
- LYWWILDQHVTJKY-UHFFFAOYSA-N CN(C(c(cc1)ccc1Cl)=S)NC(CC(NN(C)C(c(cc1)ccc1Cl)=S)=O)=O Chemical compound CN(C(c(cc1)ccc1Cl)=S)NC(CC(NN(C)C(c(cc1)ccc1Cl)=S)=O)=O LYWWILDQHVTJKY-UHFFFAOYSA-N 0.000 description 1
- INAMTJOONRVRME-UHFFFAOYSA-O NC(CC([NH3+])=[O]S=C(CCCC(O)=O)Nc1ccccc1)=[O]S=C(CCCC(O)=O)Nc1ccccc1 Chemical compound NC(CC([NH3+])=[O]S=C(CCCC(O)=O)Nc1ccccc1)=[O]S=C(CCCC(O)=O)Nc1ccccc1 INAMTJOONRVRME-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C07D213/77—Hydrazine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/56—Amides of thiocarboxylic acids having nitrogen atoms of thiocarboxamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/83—Thioacids; Thioesters; Thioamides; Thioimides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- tumors are more responsive to treatment when anti- cancer drugs are administered in combination to the patient than when the same drugs are administered individually and sequentially.
- anti-cancer agents often act synergistically because the tumors cells are attacked simultaneously with agents having multiple modes of action. Thus, it is often possible to achieve more rapid reductions in tumor size by administering these drugs in combination.
- Another advantage of combination chemotherapy is that tumors are more likely to be eradicated completely and are less likely to develop resistance to the anti-cancer drugs being used to treat the patient.
- anti-cancer agents generally have severe side effects, even when administered individually.
- the well known anti-cancer agent taxol causes neutroperia, neuropathy, mucositis, anemia, thrombocytopenia, bradycardia, diarrhea and nausea.
- anti-cancer agents Unfortunately, the toxicity of anti-cancer agents is generally additive when the drugs are administered in combination. As result, certain types of anti-cancer drugs are generally not combined. The combined toxic side-effects of those anti-cancer drugs that are administered simultaneously can place severe limitations on the quantities that can be used in combination. Often, it is not possible to use enough of the combination therapy to achieve the desired synergistic effects. Therefore, there is an urgent need for agents which can enhance the desirable tumor attacking properties of anti-cancer agents without further increasing their undesirable side-effects, and methods for synthesizing such agents. SUMMARY OF THE INVENTION
- One embodiment of the present invention is a method of preparing a thiohydrazide product compound from a hydrazide starting compound.
- the hydrazide starting compound is represented by Structural Formula (I):
- R ) and R 2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R ! and R 2> taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.
- R s is a hydrazine protecting group
- R 5 is -H or a hydrazine protecting group.
- R 10 is -H or a substituted or unsubstituted alkyl group (preferably -H or an unsubstituted alkyl group, more preferably -H or methyl).
- the method comprises the step of reacting the starting compound with a thionylating reagent.
- Another embodiment of the present invention is a method of preparing a product compound represented by Structural Formula (Tfl):
- the method comprises the step of reacting Z-C(O)-Y-(CO)-Z or
- Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group.
- Y is a covalent bond, -C(R 7 R 8 )-, -CH 2 CH 2.
- trans-(CH CH)-, cis-(C ⁇ .-CB -, -(CC)- or a 1,4-phenylene group. More preferably,
- Y is a covalent bond or -C(R 7 R g )-.
- R 7 and R 8 are each independently -H, an aliphatic or substituted aliphatic group, or R 7 is -H and R 8 is a substituted or unsubstituted aryl group, or, R 7 and R 8> taken together, are a C2-C6 substituted or unsubstituted alkylene group.
- Each Z is a leaving group.
- Another embodiment of the present invention is a method of preparing a product compound represented by Structural Formula (IJJ) from a hydrazide starting compound represented by Structural Formula (I).
- the hydrazide starting compound is thionylated to form a thiohydrazide represented by Structural Formula (IT), as described above.
- R 5 is -H, then Z-C(O)-Y-(CO)-Z or HO-C(O)-Y-(CO)-OH and a carboxylic acid activating agent is reacted with the thiohydrazide represented by Structural Formula (IT) to form the product compound represented by Structural Formula (IE), as described above.
- R 5 is a hydrazine protecting group
- the hydrazine protecting group is first removed before reacting with Z-C(O)-Y-(CO)-Z.
- Z and Y are as described above.
- bisfthio-hydrazide amide] compounds which, as the term is used herein, refers to a compound represented by Structural Formula (I), hi addition, asymmetrical bis[thio-hydrazide amide] comounds can also be prepared by suitable modifications of these procedures.
- asymmetical bisfthio-hydrazide amide] compound refers to a compound represented by Structural Formula (IV):
- R x , R 2 , R 7 , R 8 , R 10 , and Y are as defined above.
- R 3 and R 4 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R 3 and R 4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.
- R 3 and R 4> are independently selected from R ; and R 2 .
- R n is -H or a substituted or unsubstituted alkyl group and is selected independently of R 8 .
- the method comprises a first step in which a compound represented by HOOC-Y-COOR 6 is amidated with a first thiohydrazide starting material represented by Structural Formula (II).
- R 6 is a carboxylic acid protecting group.
- the amidation forms a first intermediate represented by Structural Formula (V):
- the protecting group is then removed from the carboxylic acid to form a second intermediate with a free carboxylic acid group.
- the second intermediate is represented by Structural Formula (VI):
- R 2 can be a substituted or unsubstituted aliphatic group, preferably a substituted or unsubstituted lower alkyl group (e.g., methyl, ethyl, 72-propyl, n-butyl or n-pentyl).
- R, in Structural Formula (I)-(VI) is aryl or substituted aryl
- R 2 can be a substituted or unsubstituted aryl group, preferably a substituted or unsubstituted phenyl group.
- R, in Structural Formula ( ⁇ )-(VI) can also be a substituted or unsubstituted aliphatic group, preferably a substituted or unsubstituted lower alkyl group (e.g., methyl, ethyl, «-propyl, n-butyl or R-pentyl).
- R 2 can be a substituted or unsubstituted aryl group, preferably a substituted or unsubstituted phenyl group.
- R x in Structural Formula ( ⁇ )-(V ⁇ ) is a substituted or unsubstituted aliphatic group
- R 2 can also be a substituted or unsubstituted aliphatic group, preferably a substituted or unsubstituted lower alkyl group (e.g., methyl, ethyl, w-propyl, ?z-butyl or n-pentyl).
- R 2 in Structural Formulas ( ⁇ )-(V ⁇ ) is an aliphatic group or a substituted aliphatic group.
- R x is preferably a lower alkyl group or a substituted lower alkyl group.
- R 2 in Structural Formulas (I)-(VI) is an aryl group or a substituted aryl group, more preferably a phenyl group or a substituted phenyl group.
- R j is a substituted or unsubstituted aryl group
- R 2 is methyl or ethyl
- R 7 is -H
- R 8 is -H or methyl.
- Thionylating agent is a reagent which, under suitable, conditions, can convert a ketone, ester or amide into a thioketone, thioester or thioamide, respectively.
- thionylating agents known to one of ordinary skill in the art. Examples include Lawesson's Reagent, tetraphosphorus pentasulfide, Scheeren's reagent (P 4 S 10 - a 2 S), , P 4 S 10 -N(ethyl) 3 , Davy' Reagent and Heimgarner' reagent. Also known are conditions suitable for carrying out these conversions with thionylating agents.
- thionylating agents can similarly convert hydrazides to the corresponding thiohydrazide.
- Conditions for thionylating hydrazides are generally the same or similar to those used for thionylating ketones, esters or amides. Although some modification of those conditions may be necessary when reacting hydrazides with thionylating reagents, such modifications can readily be determined by one of ordinary skill in the art. Suitable conditions for preparing thiohydrazides from hydrazides are described in the following paragraphs.
- thionylate hydrazides typically about one equivalent of the hydrazide is reacted with the thionylating reagent in an inert solvent, h some cases, it may be desirable to use a slight excess of thionylating reagent, for example up to about 1.5 equivalents, preferably no more than about 1.1 equivalents.
- Suitable inert solvents include ethereal solvents (e.g., diethyl ether, tetrhydrofuran, glyme and 1,4-dioxane), aromatic solvents (e.g., benzene and toluene) or chlorinated solvents (e.g., methylene chloride and 1,2-dichloroethane).
- the reaction is carried out at temperatures ranging from about room temperature to about 150° C, preferably from about 75° C to about 125° C. Representative conditions for carrying out these reactions are found in Examples 1-9.
- amidating a carboxylic acid refers to converting a carboxylic acid to an amide or a hydrazide.
- Many methods for converting a carboxylic acid to an amide are known in the art. Applicants have discovered that these methods can be used to prepare to the bisfthio-hydrazide amide] compounds of the present invention.
- the carboxylic acid is first converted into a group that is more readily displaced by an amine or hydrazine than -OH.
- -OH is converted into a better leaving group.
- a “leaving group” is a group which can readily be displaced by a nucleophile.
- -OH of the carboxylic acid is converted into a better leaving group by replacing it with a halogen, typically with chloride.
- the carboxylic acid is thereby converted into an acid halide, e.g., an acid chloride.
- Reagents suitable for preparing acid chlorides from carboxylic acids are well known in the art and include thionyl chloride, oxalyl chloride, phosphorus trichloride and phosphorus pentachloride.
- each carboxylic acid group is reacted with about one equivalent or a slight excess of thionyl chloride, oxalyl chloride, phosphorus trichloride and phosphorus pentachloride in an inert solvent such as an ethereal solvent (e.g., diethyl ether, tetrahydrofuran or 1,4-dioxane), a halogenated solvent (e.g., methylene chloride or 1,2-dichloroethane) or aromatic solvent (e.g., benzene or toluene).
- an ethereal solvent e.g., diethyl ether, tetrahydrofuran or 1,4-dioxane
- a halogenated solvent e.g., methylene chloride or 1,2-dichloroethane
- aromatic solvent e.g., benzene or toluene
- the carboxylic acid is first converted into an "activated ester".
- An ester -COOR is said to be “activated” when -OR is readily displaced by an amine or hydrazine. -OR is more easily displaced as R becomes more electron withdrawing.
- Some activated esters are sufficiently stable that they can be isolated, e.g., esters wherein R is phenyl or substituted phenyl.
- diphenylmalonate can be prepared from malonyl chloride and phenol, both commercially available from Aldrich Chemical Co., Milwaukee, WL, by procedures described above
- Other activated esters are more reactive and are generally prepared and used in situ.
- Coupled ester Formation of an activated ester in situ requires a "coupling agent”, also referred to as a “carboxylic acid activating agent”, which is a reagent that replaces the hydroxyl group of a carboxyl acid with a group which is susceptible to nucleophilic displacement.
- a “coupling agent” also referred to as a “carboxylic acid activating agent”
- Examples of coupling agents include 1,1'- carbonyldiimidazole (CDI), isobutyl chloroformate, dimethylaminopropylethyl- carbodiimide (EDC), dicyclohexyl carbodiimide (DCC).
- CDI 1,1'- carbonyldiimidazole
- EDC dimethylaminopropylethyl- carbodiimide
- DCC dicyclohexyl carbodiimide
- hydrazine compound it is more common when carrying out the present invention to use the hydrazine compound as the limiting reagent.
- a weak acid such as 1-hydroxybenzotriazole (HOBt) is often added to accelerate the reaction.
- HOBt 1-hydroxybenzotriazole
- about between one to about 1.5 equivalents of HOBt relative to DCC is used, preferably between about one to about 1.2 equivalents.
- the reaction is generally carried out in inert, aprotic solvents, for example, halogenated solvents such as methylene chloride, dichloroethane and chloroform, ethereal solvents such as tetrahydrofuran, 1,4-dioxane and diethyl ether and dimethylformamide.
- aprotic solvents for example, halogenated solvents such as methylene chloride, dichloroethane and chloroform, ethereal solvents such as tetrahydrofuran, 1,4-dioxane and diethyl ether and dimethylformamide.
- Suitable reaction temperature generally range from between about 0° to about 100°, but the reaction is preferably carried out at ambient temperature. Representative conditions for carrying out these reactions are found in Examples 1-9.
- the compound represented by Structural Formula (V) comprises a carboxylic acid protecting group.
- Suitable protecting groups for carboxylic acids and conditions for protecting and deprotecting carboxylic acids with these groups are known in the art and are described, for example, in Greene and Wuts, "Protective Groups in Organic Synthesis", John Wiley & Sons (1991). The entire teachings of Greene and Wits are incorporated herein by reference.
- Specific examples of suitable carboxylic acid protecting groups for Structural Formula (V) include, but are not limited to tert- butoxy, benzoxy, phenoxy, diphenyhnethoxy, triphenylmethoxy and methoxymethyl.
- the compounds represented by Structural Formulas (I) and (II) can comprise a hydrazine protecting group.
- Amine protecting groups can also be used for protecting hydrazine groups, and conditions which are suitable for protecting and deprotecting amines with these protecting groups are also suitable for use with hydrazines.
- Protecting groups for amines amd conditions for protecting and deprotecting amines with these protecting groups are known in the art and are disclosed, for example, in Greene and Wuts, "Protective Groups in Organic Synthesis", John Wiley & Sons (1991).
- Specific examples of suitable hydrazine protecting groups include, but are not limited to, tert-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and fluoreny nethyloxycarbonyl (FMOC).
- a “straight chained hydrocarbyl group” is an alkylene group, i.e., -(CH 2 ) X -, with one or more (preferably one) methylene groups is optionally replaced with a linkage group, x is a positive integer (e.g., between 1 and about 10), preferably between 1 and about 6, more preferably between 1 and 2.
- a “linkage group” refers to a functional group which replaces a methylene in a straight chained hydrocarbyl.
- linkage groups examples include a ketone (-C(O)-), alkene, alkyne, phenylene, ether (-O-), thioether (-S-), or amine f-N(R a )]-, wherein R a is defined below.
- a preferred linkage group is -C(R 7 R 8 )-, wherein R 7 and R 8 are defined above.
- Suitable substitutents for an alkylene group and a hydrocarbaryl group are those which do not substantially interfere with the reactions described herein.
- R 7 and R 8 are preferred substituents for- an alkylene or hydrocarbyl group.
- An aliphatic group is a straight chained, branched or cyclic (non-aromatic hydrocarbon which is completely saturated or which contains one or more units of unsaturation.
- a straight chained or branched aliphatic group has from one to about twenty carbon atoms, preferably from one to about ten, and a cyclic aliphatic group has from three to about eight ring carbon atoms.
- An aliphatic group is preferably a straight chained or branched alkyl group, e.g, methyl, ethyl, 7i-propyl, z ' .sc>-propyl, «-butyl, 5ec-butyl, tert-butyl, pentyl, hexyl, pentyl or octyl, or a cycloalkyl group with three to about eight ring carbon atoms.
- C1-C20 straight chained and branched alkyl groups and C3-C8 cycloalkyl groups are also referred to herein as "lower alkyl groups”.
- Aromatic groups include carbocyclic aromatic groups such as phenyl, naphthyl, and anthracyl, and heteroaryl groups such as imidazolyl, thienyl, furanyl, pyridyl, pyrimidy, pyranyl, pyrrolyl, pyrazolyl, pyrazinyl, thiazole, oxazolyl and tetrazole.
- Aromatic groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings.
- Examples include benzothienyl, benzofuranyl, indolyl, quinolinyl, benzothiazole, benzooxazole, benzimidazole, quinolinyl, isoquinolinyl, isoindolyl, 3 -isoindolyl.
- Non-aromatic heterocyclic rings are non-aromatic carbocyclic rings which include one or more heteroatoms such as nitrogen, oxygen or sulfur in the ring.
- the ring can be five, six, seven or eight-membered. Examples include tetrahydrofuranyl, tetrahyrothiophenyl, morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, and thiazolidinyl.
- Suitable substituents on a aliphatic, aromatic non-aromatic heterocyclic or benzyl group are those which do not substantially interfere with the reactions described herein.
- “Interfering with a reaction” refers to substantially decreasing the yield (e.g., a decrease of greater than 50%) or causing a substantial amount of by- product fomiation (e.g., where by-products represent at least 50% of the theoretical yield).
- Interfering substituents can be used, provided that they are first converted to a protected form. Suitable protecting groups are known in the art and are disclosed, for example, in Greene and Wuts, "Protective Groups in Organic Synthesis", John Wiley & Sons (1991).
- Suitable substituents on an aliphatic group, non-aromatic heterocyclic group, benzylic or aryl group include, for example, -OH, halogen (-Br, -CI, -I and -F), -OR a , -O-COR a , -COR a , -CN, -NO 2 , - COOH, -SO 3 H, -NH 2 , -NHR ⁇ -N(R a R b ), -COOR a , -CHO, -CONH 2 , -CONHR ⁇ - CON(R a R b ), -NHCOR a , -NRCOR a , -NHCONH 2 , -NHCONR ⁇ , -NHCON(R a R b ), -NR c CONH 2 , -NR c CON(R a R b
- R a -R d each are independently an aliphatic, substituted aliphatic, benzyl, substituted benzyl, aromatic or substituted aromatic group, preferably an alkyl, benzylic or aryl group.
- -NR a R d taken together, can also form a substituted or unsubstituted non-aromatic heterocyclic group.
- a benzylic group, non- aromatic heterocyclic group or aryl group can also have an aliphatic or substituted aliphatic group as a substituent.
- a substituted alkyl or aliphatic group can also have a non-aromatic heterocyclic ring, a substituted a non-aromatic heterocyclic ring, benzyl, substituted benzyl, aryl or substituted aryl group as a substituent.
- a substituted aliphatic, non-aromatic heterocyclic group, substituted aryl, or substituted benzyl group can have more than one substituent.
- arylene refers to an aryl group which is connected to the remainder of the molecule by two other bonds.
- arylene refers to an aryl group which is connected to the remainder of the molecule by two other bonds.
- the structure of a 1 ,4-phenylene group is shown below:
- Phenyl hydrazine (5.4g, 50 mmol) was dissolved in dry dichloromethane (50 mL) in a 250 mL round bottom flask. Di-ter -butyl dicarbonate (10.9 g, 50 mmol) was then added with stirring at 0 °C. The resultant solution was then stirred under reflux for 3 h. Removal of the volatile components under reduced pressure afforded a colorless solid, which was washed with hexane and dried in vacuo. 10 g (yield 96%) of the product was obtained as a colorless solid, which can be used in the next step without further purification. 2.5 g (12 mmol) of this material was dissolved in dry pyridine (5 mL).
- Lawesson's Reagent (0.46 g, 1.15 mmol) in dry toluene (20 mL) was stirred under reflux for 1 h. After being cooled to room temperature, the mixture was filtered through a short column of silica gel (5 g) which was pre-washed with benzene. Removal of benzene afforded the crude product as a solid which was purified by column chromatography on silica gel using hexane/EtOAc (4 : 1 v/v) as eluant. 0.15g (60%) of thiocyclohexanoic acid N-phenylhydrazide was obtained as an off white solid.
- N-Malonyl-bisfN'-methyl-N'- thiobenzoyl)hvdrazide To a solution of thiobenzoic acid N-methylhydrazine (10 g) stirred at 0 C were added subsequently trietlrylamine (8.5 mL) and malonyl dichloride (3.05 mL). The reaction mixture was stirred for 10 min, washed with water (3x50 mL), dried over sodium sulfate and concentrated. Purification by recrystallization from methylene dichloride (35 mL) gave the product as light yellow crystals (9.0 g, 75%).
- N-Malonyl-bis[N'-methyl-N'-(thiobenzoyl hydrazide] A stirred solution of thiobenzoic acid N-methylhydrazide (1.66 g, 10 mmol) and diphenyl malonate (1.30 g, 5.08 mmol) in dry THF (100 mL) was heated to reflux for 72 h. Volatile components were then removed under reduced pressure. The crude product was purified by column chromatography on silica gel using a mixture of hexane and EtOAc as eluant (gradient from 4:1 v/v to 1: 1 v/v).
- Example 9 The compounds shown below were prepared by the procedures described above. Analytical data is provided for these compounds.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA04000245A MXPA04000245A (en) | 2001-07-10 | 2002-07-10 | Synthesis of taxol enhancers. |
JP2003512201A JP2004534847A (en) | 2001-07-10 | 2002-07-10 | Synthesis of taxol enhancer |
CA002453415A CA2453415A1 (en) | 2001-07-10 | 2002-07-10 | Synthesis of taxol enhancers |
KR10-2004-7000333A KR20040026679A (en) | 2001-07-10 | 2002-07-10 | Synthesis of taxol enhancers |
AU2002316625A AU2002316625B2 (en) | 2001-07-10 | 2002-07-10 | Synthesis of taxol enhancers |
EP02746946A EP1406868A1 (en) | 2001-07-10 | 2002-07-10 | Synthesis of taxol enhancers |
NO20040053A NO20040053L (en) | 2001-07-10 | 2004-01-07 | Synthesis of taxol enhancers |
AU2006203689A AU2006203689A1 (en) | 2001-07-10 | 2006-08-24 | Synthesis of taxol enhancers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30431801P | 2001-07-10 | 2001-07-10 | |
US60/304,318 | 2001-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003006429A1 true WO2003006429A1 (en) | 2003-01-23 |
Family
ID=23176001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/021716 WO2003006429A1 (en) | 2001-07-10 | 2002-07-10 | Synthesis of taxol enhancers |
Country Status (11)
Country | Link |
---|---|
US (4) | US6825235B2 (en) |
EP (1) | EP1406868A1 (en) |
JP (1) | JP2004534847A (en) |
KR (1) | KR20040026679A (en) |
CN (2) | CN101270069A (en) |
AU (2) | AU2002316625B2 (en) |
CA (1) | CA2453415A1 (en) |
MX (1) | MXPA04000245A (en) |
NO (1) | NO20040053L (en) |
TW (1) | TWI252847B (en) |
WO (1) | WO2003006429A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008504264A (en) * | 2004-06-23 | 2008-02-14 | シンタ ファーマスーティカルズ コーポレイション | Bis (thio-hydrazide amide) salts for cancer treatment |
WO2009073148A2 (en) * | 2007-11-28 | 2009-06-11 | Synta Pharmaceuticals Corp. | Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide) |
WO2009123704A2 (en) * | 2008-03-31 | 2009-10-08 | Synta Pharmaceuticals Corp. | Process for preparing bis(thiohydrazide amides) |
US7645904B2 (en) | 2006-09-15 | 2010-01-12 | Synta Pharmaceuticals Corp. | Purification of bis(thiohydrazide amides) |
US7652168B2 (en) | 2001-07-10 | 2010-01-26 | Synta Pharmaceuticals Corp. | Synthesis of taxol enhancers |
US7671092B2 (en) | 2001-07-10 | 2010-03-02 | Synta Pharmaceuticals Corp. | Paclitaxel enhancer compounds |
US7678832B2 (en) | 2005-08-16 | 2010-03-16 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amide) formulation |
US7750042B2 (en) | 2001-07-10 | 2010-07-06 | Synta Pharmaceuticals Corp. | Paclitaxel enhancer compound |
US7763658B2 (en) | 2003-01-15 | 2010-07-27 | Synta Pharmaceuticals Corp. | Treatment for cancers |
US7939564B2 (en) | 2006-08-31 | 2011-05-10 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
US8017654B2 (en) | 2005-04-15 | 2011-09-13 | Synta Pharmaceuticals Corp. | Combination cancer therapy with bis(thiohydrazide) amide compounds |
WO2013144228A1 (en) | 2012-03-29 | 2013-10-03 | Basf Se | Pesticidal methods using heterocyclic compounds and derivatives for combating animal pests |
US9156783B2 (en) | 2006-08-21 | 2015-10-13 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060167106A1 (en) * | 2004-11-19 | 2006-07-27 | Mei Zhang | Compounds acting at the centrosome |
AU2005306471B2 (en) * | 2004-11-19 | 2009-12-17 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amides) for increasing Hsp70 expression |
WO2006113572A1 (en) * | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Methods of increasing natural killer cell activity for therapy |
CN101223133B (en) * | 2005-05-16 | 2012-02-29 | 辛塔制药公司 | Synthesis of bis(thio-hydrazide amide) salts |
JP2010501564A (en) * | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | Bis (thiohydrazide amide) for treating melanoma |
JP2010501558A (en) * | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | Combination with bis (thiohydrazide amide) to treat cancer |
JP2010501559A (en) * | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | Bis (thiohydrazide amide) for use in preventing or delaying melanoma recurrence |
CN101134057B (en) * | 2006-09-01 | 2011-04-27 | 中山大学 | Compound medicament of natural plant extract containing paclitaxel and anticancer application thereof |
AU2007294969A1 (en) * | 2006-09-11 | 2008-03-20 | Synta Pharmaceuticals Corp. | Bis (thiohydrazide amides) formulation |
US9498528B2 (en) * | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
US20090093538A1 (en) * | 2007-01-03 | 2009-04-09 | Synta Pharmaceuticals Corp | Method for treating cancer |
WO2009064374A2 (en) | 2007-11-09 | 2009-05-22 | Synta Pharmaceuticals Corp. | Oral formulations of bis(thiohydrazide amides) |
WO2009105257A1 (en) | 2008-02-21 | 2009-08-27 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
WO2010048284A1 (en) | 2008-10-22 | 2010-04-29 | Synta Pharmaceuticals Corp. | Transition metal complexes of bis[thiohydrazide amide] compounds |
AU2009308511B2 (en) | 2008-10-22 | 2013-03-07 | Synta Pharmaceutical Corp. | Transition metal complexes of a bis[thiohydrazide amide] compound |
US8525776B2 (en) * | 2008-10-27 | 2013-09-03 | Lenovo (Singapore) Pte. Ltd | Techniques for controlling operation of a device with a virtual touchscreen |
JP5631327B2 (en) | 2008-12-01 | 2014-11-26 | シンタ ファーマシューティカルズ コーポレーション | Compounds for treating proliferative disorders |
WO2011069159A2 (en) | 2009-12-04 | 2011-06-09 | Synta Pharmaceuticals Corp. | Bis[thiohydrazide amide] compounds for treating leukemia |
WO2011133673A1 (en) | 2010-04-20 | 2011-10-27 | Synta Pharmaceuticals Corp. | Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers |
EP2776021A1 (en) | 2011-11-10 | 2014-09-17 | Synta Pharmaceuticals Corp. | Administration of a bis(thiohydrazide amide) compound for treating cancers |
WO2013103795A1 (en) | 2012-01-05 | 2013-07-11 | The Board Of Trustees Of The Leland Stanford Junior University | Bis (thiohydrazide amide) compounds for treating cancers |
CN115572249A (en) * | 2022-09-21 | 2023-01-06 | 南京红云生物科技有限公司上海分公司 | Copper ion chelating agent and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH482394A (en) * | 1966-09-14 | 1969-12-15 | Shell Int Research | Herbicidal agent |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2097737A5 (en) | 1970-07-14 | 1972-03-03 | Berlin Chemie Veb | Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4- |
DE2037257A1 (en) | 1970-07-28 | 1972-02-03 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn |
GB1272920A (en) | 1971-03-15 | 1972-05-03 | Berlin Chemie Veb | New thiosemicarbazides |
US4012360A (en) * | 1973-12-03 | 1977-03-15 | Ciba-Geigy Corporation | Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines |
JPS5091056A (en) | 1973-12-17 | 1975-07-21 | ||
US4822777A (en) * | 1987-02-27 | 1989-04-18 | Liposome Technology, Inc. | Amphotericin B/cholesterol sulfate composition |
JP2767241B2 (en) | 1987-04-15 | 1998-06-18 | ロ−ム アンド ハ−ス コンパニ− | Pesticidal N- (optionally substituted) -N'-substituted-N, N'-disubstituted hydrazines |
US4826866A (en) * | 1987-11-02 | 1989-05-02 | A. H. Robins Company, Incorporated | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics |
US5300278A (en) * | 1988-03-09 | 1994-04-05 | Cis Bio International | Process for the preparation of 99m Tc, 186 Re or 188 Re nitride complexes usable as radiopharmaceutical products |
US6013836A (en) * | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
FR2697752B1 (en) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Antitumor compositions containing taxane derivatives. |
US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
BR9405798A (en) * | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Methods for in vivo release of biological material and useful compositions thereof |
US5916596A (en) * | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US6753006B1 (en) * | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
US5665382A (en) * | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
US5840746A (en) * | 1993-06-24 | 1998-11-24 | Merck Frosst Canada, Inc. | Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases |
US5523325A (en) | 1993-09-09 | 1996-06-04 | Jacobson; Richard M. | Amidrazones and their use as pesticides |
WO1995033710A1 (en) | 1994-06-03 | 1995-12-14 | Basf Aktiengesellschaft | Carbamoyl carboxylic acid hydrazides and their use against fungi |
CA2166676C (en) * | 1995-01-09 | 2007-05-01 | Yasuhisa Fujibayashi | Diagnostic agent for hypoxia or mitochondrial dysfunction comprising radioactive copper complex of dithiosemicarbazone derivative or diamine diol schiff base derivative |
EP0851874B1 (en) * | 1995-09-22 | 1999-09-15 | Novo Nordisk A/S | Novel variants of green fluorescent protein, gfp |
US5739686A (en) * | 1996-04-30 | 1998-04-14 | Naughton; Michael J. | Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection |
US5753200A (en) * | 1996-10-07 | 1998-05-19 | Solvay Minerals, Inc. | Sodium metabisulfite process |
US6235787B1 (en) * | 1997-06-30 | 2001-05-22 | Hoffmann-La Roche Inc. | Hydrazine derivatives |
GB9727524D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Synergistic antitumor composition containing a biologically active ureido compound |
TW479053B (en) * | 1998-10-19 | 2002-03-11 | Agro Kanesho Co Ltd | Hydrazineoxoacetamide derivatives and pesticides |
ES2161594B1 (en) * | 1998-12-17 | 2003-04-01 | Servier Lab | NEW DERIVATIVES OF HYDRAZIDE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US6322303B1 (en) * | 2000-05-12 | 2001-11-27 | David M. John | Dunnage bag and method of making same |
EP1164126A1 (en) * | 2000-06-16 | 2001-12-19 | Basf Aktiengesellschaft | Salicylic acid hydrazide derivatives, process and intermediates for their preparation, agents containing them and their use for combatting damaging fungi |
US6365745B1 (en) * | 2000-07-14 | 2002-04-02 | Sumika Fine Chemicals Co., Ltd. | Method for producing hydrazine derivative |
US6656971B2 (en) * | 2001-01-25 | 2003-12-02 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
TWI231211B (en) * | 2001-05-01 | 2005-04-21 | Abbott Lab | Compositions and methods for enhancing the bioavailability of pharmaceutical agents |
EP1387678A1 (en) * | 2001-05-03 | 2004-02-11 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation |
US6602907B1 (en) * | 2001-06-08 | 2003-08-05 | University Of Central Florida | Treatment of breast cancer |
WO2003000638A1 (en) * | 2001-06-20 | 2003-01-03 | Kuraray Co., Ltd. | Process for preparation of 2-oxocarboxylic acid esters |
TWI332943B (en) | 2001-07-10 | 2010-11-11 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
US6924312B2 (en) * | 2001-07-10 | 2005-08-02 | Synta Pharmaceuticals Corp. | Taxol enhancer compounds |
TWI297335B (en) | 2001-07-10 | 2008-06-01 | Synta Pharmaceuticals Corp | Taxol enhancer compounds |
TWI252847B (en) * | 2001-07-10 | 2006-04-11 | Synta Pharmaceuticals Corp | Synthesis of taxol enhancers |
MXPA02010231A (en) * | 2001-11-27 | 2004-12-13 | Warner Lambert Co | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases. |
CN100462359C (en) * | 2001-11-28 | 2009-02-18 | 科学研究和应用咨询公司 | 5-sulfanyl-4H-1,2,4-triazole derivatives and their use as a medicament |
TW200408407A (en) | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
KR100958618B1 (en) * | 2002-12-31 | 2010-05-20 | 동부일렉트로닉스 주식회사 | method for forming a semiconductor device |
TWI330079B (en) * | 2003-01-15 | 2010-09-11 | Synta Pharmaceuticals Corp | Treatment for cancers |
AU2006228035B2 (en) | 2003-01-15 | 2010-02-18 | Synta Pharmaceuticals Corp. | Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer |
MXPA05008335A (en) | 2003-02-11 | 2006-05-04 | Vernalis Cambridge Ltd | Isoxazole compounds as inhibitors of heat shock proteins. |
KR100575251B1 (en) | 2003-03-03 | 2006-05-02 | 재단법인서울대학교산학협력재단 | Pharmaceutical composition for treatment of cancer containing p38/JTV-1 as an effective component and screening method for pharmaceutical composition for treatment of cancer |
EP1493445A1 (en) | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
KR100544347B1 (en) * | 2003-12-11 | 2006-01-23 | 한국생명공학연구원 | Pharmaceutical compositions of diaryl-isoxazole compounds for the prevention and treatment of cancers |
US20050288347A1 (en) | 2004-03-26 | 2005-12-29 | Hodge Carl N | Certain triazole-based compounds, compositions, and uses thereof |
BRPI0512526A (en) * | 2004-06-23 | 2008-03-11 | Synta Pharmaceuticals Corp | compound, pharmaceutical composition, method for treating a cancer patient and method for preparing a bis (thiohydrazide amide) di-salt |
US20060142393A1 (en) * | 2004-09-16 | 2006-06-29 | Sherman Matthew L | Bis(thio-hydrazide amides) for treatment of hyperplasia |
AU2005306471B2 (en) * | 2004-11-19 | 2009-12-17 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amides) for increasing Hsp70 expression |
US20060167106A1 (en) * | 2004-11-19 | 2006-07-27 | Mei Zhang | Compounds acting at the centrosome |
JP5123671B2 (en) | 2005-02-17 | 2013-01-23 | シンタ ファーマシューティカルズ コーポレーション | Compounds for the treatment of proliferative diseases |
CA2604907A1 (en) * | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Combination cancer therapy with bis(thiohydrazide) amide compounds |
WO2006113493A2 (en) | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Methods of determining cancer prognosis via natural killer cell activity |
WO2006113572A1 (en) | 2005-04-15 | 2006-10-26 | Synta Pharmaceuticals Corp. | Methods of increasing natural killer cell activity for therapy |
CN101223133B (en) * | 2005-05-16 | 2012-02-29 | 辛塔制药公司 | Synthesis of bis(thio-hydrazide amide) salts |
JP2009504740A (en) * | 2005-08-16 | 2009-02-05 | シンタ ファーマシューティカルズ コーポレーション | Bis (thio-hydrazide amide) formulation |
SI22254A (en) | 2006-04-13 | 2007-10-31 | Univerza V Ljubljani Fakulteta Za Farmacijo | New arylsulphonohydrazide murc and murd enzyme inhibitors |
AU2007288337B2 (en) | 2006-08-21 | 2012-02-16 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
JP2010501559A (en) | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | Bis (thiohydrazide amide) for use in preventing or delaying melanoma recurrence |
JP2010501564A (en) | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | Bis (thiohydrazide amide) for treating melanoma |
WO2008024298A1 (en) | 2006-08-21 | 2008-02-28 | Synta Pharmaceuticals Corp. | Bis(thiohydrazide amides) for inhibiting angiogenesis |
NZ575350A (en) | 2006-08-21 | 2012-02-24 | Synta Pharmaceuticals Corp | Bis(phenylcarbonothioyl)hydrazide derivatives |
JP2010501558A (en) | 2006-08-21 | 2010-01-21 | シンタ ファーマシューティカルズ コーポレーション | Combination with bis (thiohydrazide amide) to treat cancer |
AU2007290490B2 (en) | 2006-08-31 | 2011-09-08 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
AU2007294969A1 (en) | 2006-09-11 | 2008-03-20 | Synta Pharmaceuticals Corp. | Bis (thiohydrazide amides) formulation |
CA2662554A1 (en) | 2006-09-14 | 2008-03-20 | Synta Pharmaceuticals Corp. | Compounds for the treatment of angiogenesis |
US7645904B2 (en) * | 2006-09-15 | 2010-01-12 | Synta Pharmaceuticals Corp. | Purification of bis(thiohydrazide amides) |
US20090093538A1 (en) * | 2007-01-03 | 2009-04-09 | Synta Pharmaceuticals Corp | Method for treating cancer |
WO2008136976A2 (en) | 2007-04-30 | 2008-11-13 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
US8729111B2 (en) | 2007-08-07 | 2014-05-20 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
WO2009064374A2 (en) | 2007-11-09 | 2009-05-22 | Synta Pharmaceuticals Corp. | Oral formulations of bis(thiohydrazide amides) |
US8637704B2 (en) | 2007-11-28 | 2014-01-28 | Synta Pharmaceuticals Corp. | Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide) |
TW200940050A (en) * | 2007-11-28 | 2009-10-01 | Synta Pharmaceuticals Corp | Polymorphs of N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide) |
-
2002
- 2002-07-09 TW TW091115205A patent/TWI252847B/en not_active IP Right Cessation
- 2002-07-10 AU AU2002316625A patent/AU2002316625B2/en not_active Ceased
- 2002-07-10 CA CA002453415A patent/CA2453415A1/en not_active Abandoned
- 2002-07-10 CN CNA2008100928683A patent/CN101270069A/en active Pending
- 2002-07-10 KR KR10-2004-7000333A patent/KR20040026679A/en not_active Application Discontinuation
- 2002-07-10 CN CNB02817724XA patent/CN100398516C/en not_active Expired - Fee Related
- 2002-07-10 JP JP2003512201A patent/JP2004534847A/en active Pending
- 2002-07-10 MX MXPA04000245A patent/MXPA04000245A/en not_active Application Discontinuation
- 2002-07-10 EP EP02746946A patent/EP1406868A1/en not_active Ceased
- 2002-07-10 US US10/193,076 patent/US6825235B2/en not_active Expired - Fee Related
- 2002-07-10 WO PCT/US2002/021716 patent/WO2003006429A1/en active Application Filing
-
2004
- 2004-01-07 NO NO20040053A patent/NO20040053L/en not_active Application Discontinuation
- 2004-03-24 US US10/807,919 patent/US7074952B2/en not_active Expired - Fee Related
-
2006
- 2006-05-24 US US11/440,429 patent/US7435843B2/en not_active Expired - Fee Related
- 2006-08-24 AU AU2006203689A patent/AU2006203689A1/en not_active Abandoned
-
2008
- 2008-08-29 US US12/231,217 patent/US7652168B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH482394A (en) * | 1966-09-14 | 1969-12-15 | Shell Int Research | Herbicidal agent |
Non-Patent Citations (10)
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7652168B2 (en) | 2001-07-10 | 2010-01-26 | Synta Pharmaceuticals Corp. | Synthesis of taxol enhancers |
US7750042B2 (en) | 2001-07-10 | 2010-07-06 | Synta Pharmaceuticals Corp. | Paclitaxel enhancer compound |
US7671092B2 (en) | 2001-07-10 | 2010-03-02 | Synta Pharmaceuticals Corp. | Paclitaxel enhancer compounds |
US7763658B2 (en) | 2003-01-15 | 2010-07-27 | Synta Pharmaceuticals Corp. | Treatment for cancers |
US8048925B2 (en) | 2004-06-23 | 2011-11-01 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amide) salts for treatment of cancers |
US8461208B2 (en) | 2004-06-23 | 2013-06-11 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amide) salts for treatment of cancers |
US7579503B2 (en) | 2004-06-23 | 2009-08-25 | Synta Pharmaceuticals Corp. | BIS (thio-hydrazide amide) salts for treatment of cancers |
JP2008504264A (en) * | 2004-06-23 | 2008-02-14 | シンタ ファーマスーティカルズ コーポレイション | Bis (thio-hydrazide amide) salts for cancer treatment |
US7795313B2 (en) | 2004-06-23 | 2010-09-14 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amide) salts for treatment of cancers |
US8017654B2 (en) | 2005-04-15 | 2011-09-13 | Synta Pharmaceuticals Corp. | Combination cancer therapy with bis(thiohydrazide) amide compounds |
US8623921B2 (en) | 2005-08-16 | 2014-01-07 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amide) formulation |
US7678832B2 (en) | 2005-08-16 | 2010-03-16 | Synta Pharmaceuticals Corp. | Bis(thio-hydrazide amide) formulation |
US9156783B2 (en) | 2006-08-21 | 2015-10-13 | Synta Pharmaceuticals Corp. | Compounds for treating proliferative disorders |
US7939564B2 (en) | 2006-08-31 | 2011-05-10 | Synta Pharmaceuticals Corp. | Combination with bis(thiohydrazide amides) for treating cancer |
US7645904B2 (en) | 2006-09-15 | 2010-01-12 | Synta Pharmaceuticals Corp. | Purification of bis(thiohydrazide amides) |
WO2009073148A2 (en) * | 2007-11-28 | 2009-06-11 | Synta Pharmaceuticals Corp. | Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide) |
WO2009073148A3 (en) * | 2007-11-28 | 2009-10-15 | Synta Pharmaceuticals Corp. | Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide) |
US8637704B2 (en) | 2007-11-28 | 2014-01-28 | Synta Pharmaceuticals Corp. | Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide) |
US20140350115A1 (en) * | 2007-11-28 | 2014-11-27 | Synta Pharmaceuticals Corp. | Polymorphs of n-malonyl-bis(n`-methyl-n`-thiobenzoylhydrazide) |
US9051250B2 (en) * | 2007-11-28 | 2015-06-09 | Synta Pharmaceuticals Corp. | Polymorphs of N-malonyl-bis(N′-methyl-N′-thiobenzoylhydrazide) |
WO2009123704A3 (en) * | 2008-03-31 | 2009-12-10 | Synta Pharmaceuticals Corp. | Process for preparing bis(thiohydrazide amides) |
WO2009123704A2 (en) * | 2008-03-31 | 2009-10-08 | Synta Pharmaceuticals Corp. | Process for preparing bis(thiohydrazide amides) |
WO2013144228A1 (en) | 2012-03-29 | 2013-10-03 | Basf Se | Pesticidal methods using heterocyclic compounds and derivatives for combating animal pests |
Also Published As
Publication number | Publication date |
---|---|
MXPA04000245A (en) | 2005-03-07 |
US20030069225A1 (en) | 2003-04-10 |
AU2002316625B2 (en) | 2006-05-25 |
US20060281811A1 (en) | 2006-12-14 |
US7074952B2 (en) | 2006-07-11 |
CN100398516C (en) | 2008-07-02 |
AU2006203689A1 (en) | 2006-09-14 |
US6825235B2 (en) | 2004-11-30 |
NO20040053L (en) | 2004-02-10 |
US20040229952A1 (en) | 2004-11-18 |
US20090005594A1 (en) | 2009-01-01 |
EP1406868A1 (en) | 2004-04-14 |
CN101270069A (en) | 2008-09-24 |
CN1553893A (en) | 2004-12-08 |
TWI252847B (en) | 2006-04-11 |
US7435843B2 (en) | 2008-10-14 |
US7652168B2 (en) | 2010-01-26 |
JP2004534847A (en) | 2004-11-18 |
KR20040026679A (en) | 2004-03-31 |
CA2453415A1 (en) | 2003-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003006429A1 (en) | Synthesis of taxol enhancers | |
AU2002316625A1 (en) | Synthesis of taxol enhancers | |
RU2198656C2 (en) | Sulfated amino acid derivatives and metalloproteinase inhibitors comprising thereof | |
US20040162317A1 (en) | Mono-acylated o-phenylendiamines derivatives | |
CA2397575A1 (en) | Antibacterial agents | |
EP1406869A1 (en) | Taxol enhancer compounds | |
CZ200425A3 (en) | Derivatives of aromatic dicarboxylic acids | |
AU2002316626A1 (en) | Taxol enhancer compounds | |
JP2001525392A (en) | Adamantane derivative | |
AU5650299A (en) | Benzene derivatives and medicinal use thereof | |
WO2009067856A1 (en) | Histone deacetylase inhibitor, composition and use thereof | |
CA2507137A1 (en) | Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents | |
JPS6317823B2 (en) | ||
CN113087693B (en) | Nitrogen-containing biaryl ring compound, preparation method and application | |
US20030225043A1 (en) | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same | |
US20020151718A1 (en) | Synthesis of pyrrole amides | |
RU2125040C1 (en) | Succinic acid derivatives, method of preparing same, intermediate compounds for synthesis thereof, and method of preparing intermediate compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003512201 Country of ref document: JP Ref document number: 2453415 Country of ref document: CA Ref document number: PA/a/2004/000245 Country of ref document: MX Ref document number: 1020047000333 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 77/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002316625 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002746946 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002817724X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002746946 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |